Natus Medical Incorporated (NASDAQ:NTUS) Short Interest Up 57.2% in May
Natus Medical Incorporated (NASDAQ:NTUS – Get Rating) saw strong growth in short-term interest in May. As of May 15, there were short interests totaling 1,090,000 shares, a growth of 57.2% from the total of 693,400 shares as of April 30. Based on an average daily volume of 440,300 shares, the day-to-cover ratio is currently 2.5 days. Approximately 3.2% of the company’s shares are sold short.
Several brokerages have recently released reports on NTUS. StockNews.com began covering Natus Medical shares in a research note on Thursday, March 31. They established a “Strong Buy” rating for the company. Zacks Investment Research downgraded shares of Natus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, May 3.
A number of hedge funds have recently increased or reduced their holdings in NTUS. Toroso Investments LLC bought a new stake in shares of Natus Medical in the first quarter worth $400,000. Keeley Teton Advisors LLC bought a new stake in shares of Natus Medical in the first quarter worth $641,000. Jane Street Group LLC bought a new stake in shares of Natus Medical in the first quarter worth $203,000. Captrust Financial Advisors increased its stake in Natus Medical shares by 138.3% in the first quarter. Captrust Financial Advisors now owns 1,823 shares of the company valued at $48,000 after acquiring an additional 1,058 shares during the period. Finally, State Street Corp increased its stake in shares of Natus Medical by 2.0% in the first quarter. State Street Corp now owns 1,345,374 shares of the company valued at $35,356,000 after acquiring an additional 26,928 shares during the period. Institutional investors and hedge funds own 92.35% of the company’s shares.
NTUS traded down $0.05 on Friday, hitting $32.83. The company’s stock had a trading volume of 319,192 shares, compared to its average volume of 450,621. Natus Medical has a 12-month low of $20.90 and a 12-month high of $33.93. The company’s 50-day simple moving average is $30.06 and its 200-day simple moving average is $26.25. The company has a market capitalization of $1.14 billion, a P/E ratio of 88.73 and a beta of 0.23.
Natus Medical (NASDAQ:NTUS – Get Rating) last released its quarterly earnings data on Thursday, May 5. The company reported EPS of $0.22 for the quarter, missing the consensus estimate of $0.26 per ($0.04). Natus Medical had a net margin of 2.65% and a return on equity of 10.15%. In the same quarter a year earlier, the company posted EPS of $0.16. Research analysts expect Natus Medical to post EPS of 1.44 for the current year.
Natus Medical Company Profile (Get an evaluation)
Natus Medical Incorporated provides medical device solutions focused on the diagnosis and treatment of patients with sensory and central nervous system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring and follow-up of common medical conditions in newborn care, hearing loss, neurological and neurosurgical treatments, epilepsy, sleep disorders and neuromuscular diseases.
Get news and reviews for Natus Medical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Natus Medical and related companies with MarketBeat.com’s free daily email newsletter.